Pityriasis rubra pilaris and adalimumab: Dose reduction and dose escalation strategies based on two clinical cases

Pityriasis rubra pilaris (PRP) is a rare cutaneous papulosquamous inflammatory disease which often fails to respond to conventional therapies. The off-label use of adalimumab for the treatment of PRP, have been shown to be effective in case series and case reports. In a recent literature review on the treatment of PRP with biological agents, a total of 20 patients treated with adalimumab were found. These patients were all refractory to other therapies and adalimumab was administered subcutaneously (sc) at the dose of 80 mg at week 0 and then 40 mg twice monthly for several weeks to a few months in most cases.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research